Nuvilex (PMCB) Competitors $1.04 +0.01 (+0.97%) Closing price 09/12/2025 03:51 PM EasternExtended Trading$1.06 +0.01 (+1.44%) As of 09/12/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMCB vs. ENLV, FBLG, AKTX, NAII, SNYR, PASG, CTXR, ALLR, RLYB, and NNVCShould you be buying Nuvilex stock or one of its competitors? The main competitors of Nuvilex include Enlivex Therapeutics (ENLV), FibroBiologics (FBLG), Akari Therapeutics (AKTX), Natural Alternatives International (NAII), Synergy CHC (SNYR), Passage Bio (PASG), Citius Pharmaceuticals (CTXR), Allarity Therapeutics (ALLR), Rallybio (RLYB), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical products" industry. Nuvilex vs. Its Competitors Enlivex Therapeutics FibroBiologics Akari Therapeutics Natural Alternatives International Synergy CHC Passage Bio Citius Pharmaceuticals Allarity Therapeutics Rallybio NanoViricides Nuvilex (NASDAQ:PMCB) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Does the media prefer PMCB or ENLV? In the previous week, Enlivex Therapeutics had 6 more articles in the media than Nuvilex. MarketBeat recorded 9 mentions for Enlivex Therapeutics and 3 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.30 beat Enlivex Therapeutics' score of 0.16 indicating that Nuvilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PMCB or ENLV more profitable? Nuvilex's return on equity of 4.60% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvilexN/A 4.60% 3.76% Enlivex Therapeutics N/A -58.31%-50.32% Do analysts recommend PMCB or ENLV? Enlivex Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 834.58%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Nuvilex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvilex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of PMCB or ENLV? 34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 10.2% of Nuvilex shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, PMCB or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvilexN/AN/A$30.66M$2.590.40Enlivex TherapeuticsN/AN/A-$15.01M-$0.58-1.84 Which has more volatility and risk, PMCB or ENLV? Nuvilex has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. SummaryNuvilex beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks. Get Nuvilex News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMCB vs. The Competition Export to ExcelMetricNuvilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7M$2.59B$5.87B$10.13BDividend YieldN/A56.52%5.68%4.60%P/E Ratio0.4023.5374.5225.93Price / SalesN/A534.89516.21181.52Price / CashN/A171.1637.5660.44Price / Book0.145.3712.166.29Net Income$30.66M$32.95M$3.28B$270.77M7 Day Performance8.56%1.28%0.78%3.84%1 Month Performance19.54%6.09%4.87%4.85%1 Year Performance-45.26%-2.15%60.72%26.00% Nuvilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMCBNuvilex1.5013 of 5 stars$1.04+1.0%N/A-42.5%$7MN/A0.404Upcoming EarningsShort Interest ↑ENLVEnlivex Therapeutics2.5407 of 5 stars$1.06+1.0%$10.00+843.4%-32.7%$24.83MN/A-1.6170News CoverageAnalyst ForecastShort Interest ↑FBLGFibroBiologics3.0977 of 5 stars$0.62+5.3%$13.00+1,992.1%-82.8%$24.72MN/A-1.7310News CoverageAnalyst ForecastAKTXAkari Therapeutics3.7335 of 5 stars$0.70-7.9%$5.00+614.4%-76.1%$24.45MN/A0.009Analyst ForecastShort Interest ↓High Trading VolumeNAIINatural Alternatives International1.6423 of 5 stars$3.68-1.5%N/A-44.0%$23.05M$113.80M-2.64290Positive NewsShort Interest ↓Gap DownSNYRSynergy CHC4.0739 of 5 stars$2.37-2.1%$10.00+321.9%+980.0%$22.85M$34.83M6.2440News CoveragePASGPassage Bio3.9345 of 5 stars$7.11-0.3%$75.67+964.2%-53.1%$22.66MN/A-0.39130CTXRCitius Pharmaceuticals2.3805 of 5 stars$1.29-3.0%$53.00+4,008.5%-90.6%$22.63MN/A0.0020Analyst UpgradeShort Interest ↑ALLRAllarity Therapeutics1.9322 of 5 stars$1.60+3.9%$9.00+462.5%-42.4%$22.51MN/A0.0010Short Interest ↑RLYBRallybio3.3989 of 5 stars$0.56+4.4%$5.00+792.9%-45.4%$22.42M$640K-0.6040Positive NewsShort Interest ↓NNVCNanoViricides0.1536 of 5 stars$1.40+0.7%N/A-13.7%$22.34MN/A-1.9420Short Interest ↑ Related Companies and Tools Related Companies ENLV Competitors FBLG Competitors AKTX Competitors NAII Competitors SNYR Competitors PASG Competitors CTXR Competitors ALLR Competitors RLYB Competitors NNVC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMCB) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
